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Abstract: The term neonatal sepsis is used to describe a generalized bloodstream infection of bacterial,
viral, or fungal origin which is associated with hemodynamic changes and other clinical symptoms
and signs, however, there is no unified definition. There are no basic criteria regarding differentiation
of early-onset sepsis (EOS) versus late-onset sepsis (LOS). Stratification used in studies on neonatal
sepsis also rarely includes the general condition of the newborn according to unambiguous assessment
at birth, which hampers the establishment of a clear, uniform epidemiological description of neonatal
sepsis. We aim to review the published data about the epidemiology and microbiology of sepsis in
Organization for Economic Cooperation and Development (OECD) countries. Data was also collected
on sepsis prevention programs that can be implemented in neonatal units. The outcomes of interest
were incidence or incidence density of EOS and LOS, microbiology of EOS and LOS, and data on
the methodology of the research, in particular the criteria for inclusion and exclusion of newborns
from the study. Pubmed, EMBASE, LILACS Embase, Scopus, and Google Scholar were used. For the
preselection step, inclusion criteria included: “bloodstream infection” or “neonatal sepsis” (MesH),
“very low birth weight”, and “country” full-text studies, human, and English language. Exclusion
criteria included: studies published in languages other than English and studies available only as
an abstracts. For proper selection, inclusion criteria included: information about epidemiology or
microbiology bloodstream infection (BSI), study population and case definitions, exclusion criteria,
narrative reviews, commentaries, case studies, pilot studies, study protocols, pediatric studies, and
only clinical data (without microbiology or epidemiology) or studies with only one etiological factor
analysis. The data review indicated the lack of an unequivocal, unified definition and no unambiguous
basic criteria with regard to differentiation of EOS versus LOS. Among infants <1500 g, studies
reported an EOS rate from 7% to 2%. For studies using other definitions (mostly all inborn babies),
the rate of EOS ranged from 1% to 3%. The LOS incidences were much more varied among countries;
the highest rates were in the multicenter studies focused on very low birth weight (VLBW) infants.
The main pathogens in EOS are GBS and Gram-negative bacteria in LOS. Our review data shows that
LOS microbiology is very diverse and that Gram-positive cocci, especially staphylococci, predominate
versus Gram-negative rods. Unfortunately, the lack of uniform, international prevention programs
results in high newborn morbidity and insufficient postnatal prevention of late-onset infections.
Keywords: neonatal sepsis; bloodstream infections; very low birth weight neonates; epidemiology;
prevention; probiotics
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1. Introduction
Infection in newborns, especially mild cases, remains a significant problem of contemporary
medicine. In highly developed countries, one reason for this situation is the increasing number of
multiple pregnancies and preterm births [1], such as in the United States (US), as compared with the
period 1990 to 2007; the proportion of deliveries before 28 weeks of gestation in 1990 was 71% and
77% in 2007, and pregnancies with a higher number of fetuses (three and more) were observed twice
more often than previously [2]. The second reason for the increasing proportion of infants among
hospitalized patients is progression of survival rate of newborns with very low birth weight (VLBW)
in modern neonatal intensive care units (NICU), however, this situation is invariably associated with
high incidence of both early and late infections [3–8].
The most frequently observed infection in neonatal wards is bloodstream infection (BSI). According
to a European point prevalence survey (2011–2012, based on European Center for Disease Prevention
and Control (ECDC) methodology), BSI accounts for 44.6% of all healthcare-associated infections
(HAIs) [9].
Thus, we aimed here to review and summarize the recently published data that most closely
describe the incidence and microbiology of BSI in high-income countries. We chose Organization for
Economic Cooperation and Development (OECD) countries as these have comparable rates of survival
among premature infants. Data were also collected on BSI prevention programs and procedures that
can be implemented in neonatal units.
2. Methods
2.1. Data Sources
The outcomes of interest were incidence or incidence density of EOS and LOS, microbiology of
EOS and LOS, and data on the methodology of the research, in particular the criteria for inclusion and
exclusion of newborns from the study. In the epidemiological and microbiological part of the study it
was a two-stage search, performed by two review authors using MEDLINE via Pubmed, EMBASE,
LILACS Embase, Scopus, and Google Scholar from 1980 to September 31, 2018. Two review authors
independently performed a search concerning epidemiology and microbiology of BSI. The search was
restricted to OECD countries [10]. The literature review on BSI prevention and control was performed
by three review authors.
2.2. Search Strategy and Study Selection
For the preselection step, inclusion criteria included: “bloodstream infection” or “neonatal sepsis”
(MesH), “very low birth weight”, and “country” full-text studies, human, English language. Exclusion
criteria included: studies published in languages other than English and studies available only as
an abstracts.
For proper selection, inclusion criteria included: information about epidemiology or microbiology
BSI, study population and case definitions, especially, data on BSI or neonatal sepsis microbiology
and incidence rates with reported denominators, specified dates of the data collection period, and a
description of the methods used including study population, the definition of BSI, and eligibility rules
for early- and late-onset cases of BSI. Exclusion criteria included: narrative reviews, commentaries, case
studies, pilot studies, study protocols, pediatric studies, and only clinical data (without microbiology
or epidemiology) or studies with only one etiological factor analysis.
Initially, other sources of the data on incidence rates of neonatal sepsis etc. in non-English
journals and governmental reports were also reviewed, but methodology and definitions used in these
sources did not appear to be adequately precise, and therefore only the search described above was
then presented.
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For proper selection, two author reviewers independently reviewed the titles and all abstracts.
A study was eligible for inclusion if the epidemiology of BSI was provided at the national, regional,
or multicenter level. In the case of a dearth of multicenter data, single-center study data were
also included.
From the included studies, the following information data were extracted: country, case definition,
study population, as well as and inclusion and exclusion criteria, time period, incidence rates and
microbiology; if possible, we also extracted birth-weight specific BSI incidence rates and specific
microbiology according to early-onset (EOS) or late-onset cases of BSI (LOS) or neonatal sepsis (Table 1).
When there were multiple publications from the same country, the data from the most recent publication
were only included once.
J. Clin. Med. 2019, 8, 1750 4 of 24
Table 1. Characteristics of the collected studies on neonatal sepsis and bloodstream infections incidence rate in Organization for Economic Cooperation and
Development (OECD) countries (in alphabetical order).
Country Population: Criteria of Including National/Regional Network orDatabase Case Definition References
Austraila & N. Zealand,
2002–2012 all inborn babies
Australasian Study Group for Neonatal
Infections (ASGNI) EOS: 48 h of life [11]
Australia, 2008–2016 CLABSI and PLABSI in neonatal ICUs Victorian Healthcare Associated InfectionSurveillance System
CDC definitions, NHSN methodology, LOS: 48 h
of life [12]
Australia & N. Zeland,
2005–2007
all inborn babies, born <32 weeks of
gestation 29 tertiary NICUs EOS: 48 h of life [13]
Austria, 1988–1994 all babies 1 center study EOS: <7 days of life [14]
Belgium, 2002–2011 all infants, inborn or hospitalised forat least 3 days 1 center study: tertiaty NICU
LOS: more than 72 h of life, only
laboratory-confirmed BSI [15]
Canada, 2005–2007 all inborn babies, born <32 weeks ofgestation 26 tertiary NICUs EOS: 72 h of life [13]
Denmark, 2010–2013 all infants, inborn or hospitalisedborn <28 weeks of gestation 1 center study: tertiaty NICU
EOS: <7 days of life, only laboratory-confirmed
BSI [16]
Denmark, 2005 all infants, inborn or hospitalised 1 center study: tertiaty NICU LOS: more than 48 h of life, onlylaboratory-confirmed BSI [17]
Estonia, 2004–2008 all inborn babies 1 center study: NICU and paediatricintensive care unit CDC definitions, only laboratory-confirmed BSI [18]
Finland, 1999–2006 all inborn babies 1 center study CDC definitions, only laboratory-confirmed BSI [19]
France, 2004–2005 all inborn babies Alsace, 9 tertiary NICUs EOS: 72 h of life [20]
France, 2007 all inborn babies Alsace, 9 tertiary NICUs LOS: between 72 h and 90 days of life [21]
Germany, 2000–2005 VLBW infants Neo-KISS Neo-KISS definition, LOS: more than 72 h of life [22]
Germany, 2010–2011 VLBW infants Neo-KISS Neo-KISS definition, LOS: more than 72 h of life [23]
Greek, 2012–2015 neonates admitted to participatingNNUs
16 NICUs participating in the neonIN
infection surveillance network
EOS: 48 h of life, positive blood, cerebrospinal
fluid or urine culture and were treated with at
least 5 days of antibiotics
[24]
Ireland, 2001–2014 all newborn infants, only“culture-proven” 1 center study: tertiaty NICU
EOS: <7 days of life, LOS more than 7 days of life
only laboratory-confirmed BSI [25]
Israel, 1995–1998 VLBW infants survived at least 3 days national cohort LOS: more than 72 h of life [26]
Israel, 1995–2005 VLBW infants Israel Neonatal Network undefined [27]
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Table 1. Cont.
Country Population: Criteria of Including National/Regional Network orDatabase Case Definition References
Israel, 2007–2013 population-based study 1 center study EOS: <7 days of life [28]
Italy, 2006–2010 all inborn babies 1 center study CLABSI only [29]
Japan, 2006 to 2008 all newborn infants, only“culture-proven” 5 NICUs only laboratory-confirmed BSI [30]
Mexico, 2004–2007 neonates admitted to the neonatalICUs 1 center study LOS: more than 72 h of life [31]
Netherlands, 2007 all infants with catheter 1 center study CLABSI only [32]
North America, 1997–2010 VLBW infants 313 NICUs LOS: more than 72 h of life, onlylaboratory-confirmed BSI [33]
Norwey, 1999–2000 all infants with gestational age of <28weeks or birth weight of <1000 g
national cohort of extremely premature
infants EOS: diagnosed to day 7 of life [34,35]
Poland, 2009 VLBW infants Polish Neonatology SurveillanceNetwork Neo-KISS definition, EOS: 72 h of life [36,37]
South America countries,
2001–2013 inborn VLBW infants 26 tertiary NICUs LOS: more than 72 h of life [38]
South Korea, 1997–1999 all infants, inborn or hospitalised 4 neonatal centers LOS: more than 72 h of life [39]
Spain, 2002–2005 VLBW infants SEN1500 network by Spanish Society ofNeonatology undefined [40]
Sweden, 2004–2007
extremely premature infants, born
before 27 weeks of gestation and
survived their first year of life
nationwide Swedish prospective cohort
study
only clinical sepsis with negative blood culture
and treated for a min. of 5 days [41]
Switzerland, 2011–2015 all newborn infants admitted totertiary care ICUs the Swiss Pediatric Sepsis Study
EOS: 72 h of life and/or LOS if onset of infection
was ≤48 h after admission, only
laboratory-confirmed BSI
[42]
Turkey, 2003–2010 preterm infants with gestational ageof <37 weeks, only “culture-proven” 1 center study
EOS: 72 h of life, LOS more than 72 h of life, only
laboratory-confirmed BSI [43]
United Kingdom, 2005–2014 undefined neonIN: 30 NICUs only laboratory-confirmed BSI treated with atleast 5 days of appropriate antibiotics [44]
USA, 1998–2000 VLBW and extremely prematureinfants
national: NICHD Neonatal Research
Network EOS: 72 h of life [45]
CLABSI, central line-associated bloodstream infection; PLABSI, peripheral venous catheter-associated bloodstream infection; EOS, early-onset sepsis; CDC, Centers for Disease Control;
LOS, late-onset sepsis; VLBW, very low birth weight; BSI, bloodstream infection; NICU, neonatal intensive care units,
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3. Results
A total of 4871 articles were identified, 199 articles were included in the proper selection stage
after being screened according to titles and abstracts. Finally, 35 studies which fulfilled the eligibility
criteria were included for the review (Table S1).
The included studies represented data from 27 of the 36 OECD countries, primarily across Europe,
Asia, and the US (Table 1). There were more available data on incidence rate (30 studies, 26 countries)
than on microbiology of early-onset EO and late-onset LO BSI (28 studies, 25 countries). The country,
time period, case definition applied, and incidence rates of BSI in the included studies are shown in
Table 1.
Fourteen studies were multicenter studies [11–13,24,26,27,30,33,36–40,42,44,45] one was a regional
study [20], and five were national studies [22–24,27,34,35,41], however, twelve studies were single-center
studies [14–19,25,28,29,31,32,43] (Table 1). Most study populations comprised inborn babies admitted
to the neonatal unit. Inclusion criteria were based on birth weight (mostly below 1500 g) or gestational
age, most accounted for all inborn babies (17 studies). In two studies, from Italy and Netherlands,
the surveillance included only neonates with catheters (peripheral or central venous catheter, CVC).
One study included a national cohort of extremely premature infants, Norway. With the exception of
studies from the US (1991–1993), Austria (1988–1994), and France (1984) all studies included data from
the last 20 years. The studies from Belgium, Finland, Australia, and New Zealand, and Israel covered
the longest periods.
Limited data were retrieved from some regions and many countries, but 25.7% of the OECD
countries were not represented. Furthermore 12 (35.3%) studies were single-center studies with
unknown representativeness.
3.1. Case Definitions for BSI
It is generally accepted to use the term neonatal sepsis to describe a systemic condition initially
evoked by bacteria, viruses, or fungi and which is accompanied with hemodynamic changes and other
clinical manifestations leading to substantial morbidity and mortality in neonates, however, despite
many years of clinical experience in diagnosis and treatment of neonates with confirmed or suspected
sepsis, there is no commonly accepted definition of neonatal sepsis. Sometimes, the definition of
sepsis erroneously includes isolation of a pathogen from normally sterile body fluid, such as blood or
cerebrospinal fluid, which laboratory finding should be described as bacteremia. Since practically all
clinical features and laboratory data of sepsis are induced by a burst of the potent proinflammatory
cytokines, the term clinical sepsis (or systemic inflammatory response syndrome, SIRS) has also been
used in literature in parallel to neonatal sepsis [46,47]. From an epidemiological point of view sepsis is
a bloodstream infection (BSI).
Unfortunately, our data review indicated the lack of an unequivocal, unified definition. There are
no unambiguous basic criteria with regard to differentiation of EOS versus LOS. Stratification in the
research also rarely includes newborns’ general condition according to unambiguous assessment at
birth; most program data refer to “inborn babies” without additional qualifying criteria. Both of these
factors make it impossible to establish a clear description of the epidemiology of neonatal sepsis.
In multicenter studies targeting VLBW neonates, the most commonly applied definition was that
of the Centers for Disease Control and Prevention (CDC), used in three studies. The definition used in
the Neo-KISS (a surveillance system for VLBW infants in Germany) and ECDC was applied in two
studies (Poland and Germany) (Table 1). The remaining studies used their own definition, based on a
combination of clinical signs and different time to recognition of EOS and LOS, mostly 48 or 72 h of life,
but sometimes this was five or seven days (Table 1).
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3.2. Comparison of BSI Rate by Case Definition, Date of Onset (Early and Late), and Birth Weight Category
We present the rate of BSI by case definition, gestational age, and birth weight category (Table 2).
Among infants <1500 g, studies using CDC or Neo-KISS definitions reported an EOS rate of 7% in
Poland, 5% in Spain, and about 2% in the US and Israel. For studies using other definitions (mostly all
inborn babies), the rate of EOS ranged around 1% to 3%, except 6.6% in Denmark. In a Norwegian
national cohort of extremely premature infants, the EOS rate was 3.6% (Table 2).
Table 2. Comparison of the early-onset (EO) versus late-onset sepsis (LO)/bloodstream infections
incidence rate (in alphabetical order).
Country Rate of EO Sepsis Rate of LO Sepsis References
Australia & N. Zealand,
2005–2007 1.7% 15.1% [13]
Australia, 2008–2016 n/a
CLABSI: 2.20 per 1000 CVC-days
PLABSI: 0.67 per 1000
peripheral line-days
[12]
Austria, 1988–1994 1.9% 4.6% [14]
Belgium, 2002–2011 n/a 7.1% [15]
Canada, 2005–2007 1.3% 18.7% [13]
Denmark, 2010–2013 /
2005 6.6% 7.6% [16,17]
Estonia, 2004–2008 n/a 9.2% and 12.8 per 1000 pds [18]
Finland, 1999–2006 n/a 3.2% [19]
France, 2004–2005 1.08% n/a [20]
France, 2007 n/a 4.9% [21]
Germany, 2010–2011 n/a 5.7 per 1000 pds [23]
Greek, 2012–2015 0.4% 4.5% [24]
Ireland, 2001–2014 0.1% 0.2% [25]
Israel, 1995–1998 n/a 30.1% [26]
Israel. 1995–2005 2.4% n/a [27]
Japan, 2006–2008 0.13% 0.61% [30]
Mexico, 2004–2007 3.28% 1.08% [31]
Netherlands, 2007 n/a 18.1 per 1000 pds CLABSI,catheter-associated BSI, only [32]
North America,
19978–2010 1.0% 12.2% [33]
Norway, 1999–2000 3.6% 9.7% [34,35]
Poland, 2009 7.0%
25.3%
CLABSI: 8.6 per 1000 CVC-days




2001–2013 n/a 22.2% [38]
South Korea, 1997–1999 29.3 per 1000 live births 7.2 per 1000 live births [39]
Spain, 2002–2005 5.0% 29.4% [40]
Sweden, 2004–2007 66% [41]
Switzerland, 2011–2015 0.28 per 1000 live births 0.86 per 1000 live births [42]
Turkey, 2003–2010 2.3% 12.9% [43]
United Kingdom,
2005–2014
0.7 per 1000 live births
and 5.5 per 1000 neonatal
admissions
6.1 per 1000 live births and 48.8
per 1000 neonatal admissions [44]
USA, 1998–2000 1.5% 21% [45]
central line catheter-associated bloodstream infections, CLABSI; patient days, pds; peripheral venous
catheter-associated bloodstream infections, PLABSI; CVC, central venous catheter.
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The LOS incidence rate was much more varied among countries; the highest rates were in the US,
South American countries, Poland, and Spain in multicenter studies focused on VLBW infants. In a few
studies, incidence rates were stratified by birth weight or gestational age (Table 3), the incidence rates
were surprisingly similar in the US and Poland, and rates in Germany were lower in each newborn
group (Table 3).
Table 3. Comparison of the late-onset (LO) sepsis incidence rates stratified by birth weight or gestation
age (in alphabetical order).
Country Rate of LO Sepsis: Stratification by Birth Weight or Gestation Age References
Australia and N.













2010–2011 <1000 g: 8.5 per 1000 pds 1001–1499 g: 4.0 per 1000 pds [22]
Italy, 2006–2010 <750 g: 11.6 per1000 pds *
751–1000 g: 8.6
per 1000 pds * 1001–1500 g: 4.7 per 1000 pds * [29]
Poland, 2009 <750 g: 44.6% 751–1000 g:31% 1001–1500 g: 18.0% [36,37]
USA, 1998–2000 <750 g: 42.8% 751–1000 g:28% 1001–1500 g: 11.0% [45]
* catheter-associated bloodstream infections, CLABSI only; pds, patient days.
In studies including or limited to catheter-associated BSI, the central line-associated bloodstream
infection (CLABSI) incidence was comparable. In the Netherlands, this was 18.1/1000 patient days
(pds) and 8.6/1000 pds in Poland. In Italy, this incidence was 4.7/1000 to 11.6/1000 pds, depending
on birth weight, similar to an Australian study reporting 1.2/1000 to 3.5/1000 CVC-pds. Completely
different results were found in the analysis of peripheral venous catheter -associated bloodstream
infection (PLABSI) incidence. In Australia, this was 0.67/1000 peripheral line-pds, but the incidence
was much higher in Poland, with 10.5/1000 peripheral line-pds.
There were some differences in the epidemiology of neonatal infections (both EOS and LOS)
among the analyzed studies included in this review. The main source of these differences were most
likely distinctions used by the authors in applying various parameters to describe the status of neonates
at birth or the risk of infection, as well as time lapses between birth and the onset of infection, such
as 48 h of life or 72 h of life or seven days. Likewise, different groups of neonates were used as
denominators, i.e., all infants born versus VLBW newborns only. Moreover, different definitions of
sepsis were applied. In a few studies, the basis for the diagnosis sepsis was a single positive blood
culture and prolonged antibiotic therapy. No validation of the detection and qualification of sepsis
cases was found in any studies.
The most important factor that was also closely related to intensive care in neonatal wards
seemed to be stratification of cases into groups according to the risk of infection. Unfortunately, this
methodology was applied in only a few studies, however, the most frequently used qualification was
based on gestational weight as this parameter is easy to obtain, independent from other variables, and
involves no danger of underestimation in comparison with gestational age, which is more subjective
because it relies on cooperation between the obstetrician and parturient. Stratification of neonates
according to gestational weight should be preferred in studies on the epidemiology of neonatal
infections as it is used in two of the most important research projects on neonatal infections, the
National Healthcare Safety Network (NHSN) and ECDC programs.
3.3. Microbiology of BSI
In EOS, Gram-positive bacteria predominated, particularly group B Streptococcus (GBS); the highest
percentage values were reported in French (58.5%) and British (43%) studies (Table 4). In Swedish
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research, a similar number of infections were caused by GBS (20%), coagulase-negative staphylococci
(CoNS, 30%) and Escherichia coli (25%). The situation differed in South Korea and Denmark, where the
main pathogen in EOS was S. aureus (48% and 36.6%). Mexico and Turkey dominated CoNS with a
prevalence of 55.5% and 60.9%, respectively (Table 4).
Among Gram-negative bacilli, the most frequently occurring was E. coli, which was associated
with approximately 20% of cases. E. coli predominated in EOS in a study from Israel and two studies
from North America; with respect to the latter, E. coli occurred in 33.4% of cases, whereas in the US
alone, the rate was 44%. In early infections in Poland, GBS was common (20%), but an additional
problem in that country is infections caused by Klebsiella pneumoniae (22%), also in EOS (Table 4).
Infections caused by fungi in EOS accounted for 2% to 3% of cases and the highest level was 8% in
Poland (Table 4).
In LOS, CoNS was significantly predominant, from 24.2% in Australia to 75% in the UK and
85% in the Netherlands, most often in 30% to 50% of infections. France differed in that more than
half of infections (55.5%) were caused by E. coli. In Japan, the main pathogen in LOS was S. aureus
(26% and similar in Ireland, 26.9%) apart from E.coli and Klebsiella and other Gram-negative bacillis
(24%); unexpectedly Pseudomonas spp. were also common (12%) (Table 5). In South Korea, among
Gram-positive bacteria, both CoNS and S. aureus were predominant (37.5% and 36%, respectively).
Infections caused by Gram-negative pathogens in LOS ranged from 7% in Finland to 64.4% in United
Kingdom and yeast-like fungal infections were more common than in the case of EOS, from 2% in
Switzerland to 18.8% in Turkey (Table 5).
CLABSI were very strongly associated with CoNS; this was the case in Dutch (85%) and Australian
(24.2%) studies, in line with the researchers’ expectations, however, in an Italian study of CLABSI, half
of infections (50%) were caused by yeast-like fungi (Table 5).
In summary, a predominance of Gram-positive cocci, especially GBS, was confirmed among
bacteria isolated from EOS cases. CoNS was most often found in LOS related to CLABSI and PLABSI,
although a broader range of microorganisms, including Gram-negative rods, was noted in LOS cases
(Table 5).
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Table 4. Share of the most common species of Gram-positive cocci, Gram-negative bacilli, and fungi in early-onset neonatal sepsis (in alphabetical order).
Country











Australia and N. Zealand,
2002–2012 3.0 6.0 37.0 16.5 25.0 n/a 12.5 1.0 [11]
Australia, 2008–2016 Only LO sepsis [12]
Austria, 1988–1994 6.3 12.5 28.1 21.9 0.0 9.4 18.8 3.1 [14]
Belgium Only LO sepsis [15]
Denmark 36.0 n/a 27.0 9.0 14.0 9.0 5.0 n/a [16]
Estonia, 2004–2008 Only LO sepsis [18]
Finland, 1999–2006 Only LO sepsis [19]
France, 2004–2005 1.8 2.4 58.5 9.4 22.4 0.6 4.5 n/a [20]
France, 2007 Only LO sepsis [21]
Germany, 2002–2005 Only LO sepsis [22]
Greek, 2012–2015 n/a 17.4 13.0 30.4 17.4 4.3 15.2 2.2 [24]
Ireland 12.6 14.1 38.5 n/a 14.1 n/a n/a n/a [25]
Israel, 1995–1999 Only LO sepsis [26]
Israel, 1995–2005 n/a 17.2 9.4 n/a 26.8 n/a n/a 3.0 [27]
Italy, 2006–2010 Only LO sepsis [29]
Japan, 2006 to 2008 Only LO sepsis [30]
Mexico, 2004–2007 0.0 55.5 22.2 n/a 11.1 11.1 0.0 0.0 [31]
Netherlands, 2007 Only LO sepsis [32]
Norway, 1999–2000 18.5 25.9 11.1 3.7 33.3 3.7 0.0 3.7 [34,35]
North America, 1997–2010 2.1 2.3 18.2 2.9 33.4 1.5 11.7 2.7 [33]
Poland, 2009 4.0 16.0 20.0 14.0 12.0 4.0 22.0 8.0 [36,37]
South America countries
(including Chile), 2001–2013 Only LO sepsis [38]
South Korea, 1997–1999 48.0 27.2 1.6 7.4 9.9 n/a n/a 3.3 [39]
Sweden, 2004–2007 0.0 30.0 20.0 0.0 25.0 5.0 5.0 5.0 [41]
Switzerland, 2011–2015 2.0 8.0 38.0 23.0 23.0 n/a 6.0 0.0 [42]
Turkey 4.3 60.9 8.7 8.7 4.3 0.0 13.0 0.0 [43]
United Kingdom, 2005–2014 n/a n/a 43.0 n/a 18.0 n/a n/a 0.8 [44]
USA, 1998–2000 n/a 10.7 10.7 15.5 44.0 n/a 16.7 2.4 [45]
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Table 5. Share of the most common species of Gram-positive cocci, Gram-negative bacilli, and fungi in late-onset neonatal sepsis (in alphabetical order).
Country











Australia and N. Zealand,
2002–2012 Only EO sepsis [11]
Australia *, 2008–2016 16.1 24.2 n/a 11.3 11.1 11.6 19.1 (including 8.8 Enterobacter) 5.6 [12]
Austria, 1988–1994 4.9 33.3 0.0 21.0 (Enterococcus spp. only) 1.2 2.5 22.2 18.5 [14]
Belgium 16.4 51.2 1.5 12.0 6.1 2.9 7.9 1.8 [15]
Denmark 5.8 26.9 n/a n/a 1.9 n/a 3.8 1.9 [17]
Estonia, 2004–2008 5.5 48.6 n/a 8.3 n/a 7.3 23.8 (including Serratia spp. 12.0) 3.7 [18]
Finland, 1999–2006 7.0 65.0 n/a 6.3 3.0 3.0 1.0 9.0 [19]
France, 2004–2005 Only EO sepsis [20]
France, 2007 12.7 13.6 7.3 n/a 55.5 n/a n/a n/a [21]
Germany, 2000–2005 9.8 54.2 n/a 3.9 4.6 6.3 6.4 3.1 [22]
Greek, 2012–2015 0.5 31.5 0.2 7.0 13.0 19.4 17.7 (including 8.0 Enterobacter) 10.7 [24]
Ireland 26.9 22.1 7.7 11.1 10.6 10.6 n/a n/a [25]
Israel, 1995–1999 3.9 47.3 0.3 2.9 2.8 14.7 10.3 11.1 [26]
Israel, 1995–2005 Only EO sepsis [27]
Italy **, 2006–2010 2.1 4.2 n/a 2.1 8.3 6.3 16.7 50.0 [29]
Japan, 2006 to 2008 26.0 12.0 7.0 14.0 12.0 5.0 24.0 (including 12.0 Pseudomonas spp.) n/a [30]
Mexico, 2004–2007 16.7 47.4 2.6 0.0 2.6 5.1 8.9 16.7 [31]
Netherlands **, 2007 2.5 85.0 n/a 2.5 2.5 2.5 2.5 2.5 [32]
Norwey, 1999–2000 12.0 47.0 9.0 2.0 1.0 8.0 10.0 10.0 [34,35]
North America, 1997–2010 15.4 28.3 3.1 6.8 6.2 6.8 9.6 10.5 [33]
Poland, 2009 7.8 62.7 n/a 6.6 6.6 6.8 5.9 3.8 [36,37]
South America countries
(including Chile), 2001–2013 8.7 44.3 n/a 5.7 3.8 9.5 5.6 7.0 [38]
South Korea, 1997–1999 36.0 37.5 0.0 7.8 7.8 n/a n/a 10.9 [39]
Sweden, 2004–2007 5.9 67.8 2.0 3.0 1.3 3.6 4.2 6.9 [41]
Switzerland, 2011–2015 15.3 36.5 15.3 9.1 24.7 n/a 13.0 2.3 [42]
Turkey 5.5 49.2 5.5 4.7 0.8 3.9 11.7 18.8 [43]
United Kingdom, 2005–2014 8.0 75.0 5.0 12.8 32.0 21.0 11.6 4.0 [44]
USA, 1998–2000 7.8 47.9 2.3 12.2 4.9 4.0 8.5 13.9 [45]
Notes: * central line catheter-associated bloodstream infections, CLABSI, and peripheral venous catheter-associated bloodstream infections, PLABSI; ** central line catheter-associated
bloodstream infections, CLABSI only.
J. Clin. Med. 2019, 8, 1750 12 of 24
Data on the microbiology of neonatal sepsis collected in this review confirm already known
discrepancies between the etiologies of EOS and LOS, as pathogens isolated from EOS cases are mostly
derived from the mother’s vaginal and skin microbiota. There are, however, notable exceptions, mostly
related to GBS infections, as has been found and documented by molecular typing where very early
infections are caused by horizontally transmitted hospital GBS strains [48]. Accordingly, prophylaxis
for early-onset neonatal sepsis can be attributed to surveillance of antenatal infections performed under
the framework of obstetric care by qualified personnel, although standard surveillance in neonatal
wards should start immediately after birth to protect infants from early infections transmitted during
or immediately following labor.
It should be noted that this review of infections reported and analyzed in high-income countries
revealed that most infections (both EOS and LOS) are caused by GBS, S. aureus, and E. coli, regardless of
the geographical and cultural differences among patients. This may also suggest that the epidemiology
of neonatal infections in these countries reflects high levels of standardization of intensive care.
The unusual prevalence of BSI Candida spp. in Italian neonatal intensive care units NICUs may be an
early reflection of a new shift in neonatal sepsis etiology to emerging infections caused by C. auris.
Owing to difficulties in identification, C. auris isolates may easily be misdiagnosed as other Candida
species. Infections caused by this new pathogen have been increasingly reported from India, China,
and also the US [49], although the US data included in this review do not indicate this tendency.
3.4. Prevention and Control of BSI
Actually, only EOS can be prevented using a proven strategy based on appropriate administration
of antibiotics (maternal intrapartum antibiotic prophylaxis, IAP) to stop vaginal colonization by GBS
and prevent bacteria from reaching the newborn’s oral cavity and upper respiratory tract. At the
moment, there are no other approved and implemented methods to prevent EOS and LOS in neonates.
It should be mentioned that there are new strategies to detect the threat of EOS, regardless of its
etiology, on the basis of serial physical examinations, however, this approach cannot be regarded
as preventive. These strategies are implemented in NICUs to reduce laboratory costs and to limit
overuse of antibiotics [50,51]. The most commonly used among these strategies are related to antibiotic
stewardship principles adopted in many NICUs, sometimes under pressure from global campaigns for
the prudent use of antibiotics promoted by international and national organizations such as the World
Health Organization (WHO), the Infectious Diseases Society of America, the CDC, and the ECDC.
In other cases, these strategies are adopted in NICUs in a more reasoned way, based on studies showing
the effectiveness of such restrictions. Indeed, there are several studies indicating that monitoring of
antibiotic prescribing can result in reduction of unnecessary antibiotic use in the NICU [52].
3.5. Intrapartum Antibiotic Prophylaxis (IAP)
The incidence of GBS-caused EOS before introduction of IAP into practice was three to four per
1000 live births. When the first CDC guidelines for IAP were issued in the US during the 1990s, this
rate had declined to less than 0.25/1000 live births [52,53]. After the CDC, the American Academy
of Pediatrics (AAP), the American College of Obstetricians, and other US organizations issued the
most current recommendations which are to be followed for the administration of GBS intrapartum
prophylaxis. This procedure is now accepted by the overwhelming majority of national guidelines.
Recent reviews on the effectiveness of IAP show that most cases of EOS caused by GBS can be prevented.
There are now two methods, routine culture-based screening and risk-based management, which
are used to identify mothers requiring IAP during labor [54]. This policy has been implemented in
over 90 countries, although microbiological screening for GBS carriage has only been used in 30% of
the countries and clinical risk factor screening has been used for decision making in the remaining
countries [55].
IAP has some limitations and links to adverse short- or long-term neonatal effects [56], although
there is only one report on serious outcomes of IAP, such as cerebral palsy. Seven observational studies
J. Clin. Med. 2019, 8, 1750 13 of 24
showing that IAP alters the infant microbiome were recently analyzed by Seedat [57], however, the
clinical significance of the alterations is unknown. There are also observational reports on increased
antimicrobial resistance of the gut microbiota bacteria after IAP, however, the data contained in related
studies are rather not well documented. Another long-term negative effect of IAP on gut microbiota, is
an increased risk of noncommunicable diseases, such as allergies or obesity, which has been observed
in neonates exposed to antibiotics during early infancy [58]. Still, it is too early to estimate the negative
impact of IAP and early antibiotic treatment of the neonates and their long-term effects. Therefore, it
is possible that in the future, GBS vaccination will be applied as EOS prophylaxis during pregnancy
either alone or in combination IAP. Most probably, conjugated polyvalent vaccines against both EAO
and LOS causing serotypes of GBS will be used. Such practice may decrease GBS infection rates in
neonates more effectively than IAP alone [59].
The combined prophylaxis may also prevent late-onset GBS infection, which accounts for
approximately 40% of all GBS neonatal infections. Preterm infants are particularly susceptible to
late-onset GBS infections. Actually, neither GBS IAP nor any other neonatal EOS prevention have an
effect on late-onset bacterial infection.
3.6. Implementation of Risk Stratification Strategies for Empirical Use of Antibiotics in Preterm Neonates
There are other activities that can be regarded as a form of prophylaxis in newborns with risk
factors for EOS. Management is well described in official guidelines of the CDC [60], the AAP [61],
and the National Institute for Health and Care Excellence [62]. The main component of management
is empirical antibiotic therapy given to asymptomatic neonates with known risk factors for EOS,
with special regard to chorioamnionitis. Such an approach may reduce sepsis-related morbidity [60],
although it has been questioned by some authors [63] as it leads to treating with antibiotics infants
without sings of infection. Such overuse of empirical antibiotics may pose a hazard to unaffected infants.
Generally, exposure of neonates to antibiotics, either related to IAP or to antibiotic prophylaxis during
cesarean delivery or to empirical antibiotics given postnatally to preterm babies, is common. There is
growing evidence that exposure to antibiotics is related to increased mortality in premature infants [64].
Moreover, prolonged application of antibiotics in preterm neonates, even without proven infection,
may increase the risk of necrotizing enterocolitis (NEC), bronchopulmonary dysplasia, retinopathy,
and brain damage [65,66].
Studies on colonization of the gut in newborns and establishment of the gut microbiota show
that antibiotics given after birth alter the microbiota composition, enabling its early colonization
with potential pathogens derived from the hospital environment and inhibiting colonization with
bifidobacteria found in the gut microbiota of neonates born vaginally from healthy mothers [67].
Prolonged, empirical antibiotic treatment severely impairs diversity of the gut microbiota, and promotes
pathogens associated with neonatal sepsis which are only minor members of the healthy microbiota [68].
Both the untoward effects related to empirical antibiotic treatment of anyway well-appearing term
or late-preterm newborn with risk factors for sepsis and the risk of less significant but common NICU
complications, argues in favor of a more carefully thought out management of newborns with sepsis
risks [51]. Therefore, to limit antibiotic overtreatment related to empiric therapy given to asymptomatic
newborns, new management strategies based on scheduled serial clinical observations, online sepsis
risk calculations, and optimized antibiotic dosages have been recently proposed as an alternative to
unlimited empiric antibiotics and further evaluation [69,70].
3.7. Surveillance
External, nonmaternal risk factors are associated with high intensity of various medical procedures
related to the care of newborns with VLBW. These include the use of corticosteroids in newborns
with impaired breathing that lower their own neonatal immune response [71] and the necessity for
diagnostic and therapeutic invasive procedures (intravascular catheters, respiratory support, and
parenteral nutrition), which are risk factors of neonatal LOS [72–75]. The risk of colonization with
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undesirable microorganisms also increases with long-term hospitalization and intensive care of a
newborn, especially in overcrowded wards with insufficient staff who are overworked [76–79]. In the
US, the average hospital stay for newborns with birth weight <800 g is 112 days, and a central catheter
(including an umbilical catheter) and mechanical ventilation are used in this group of premature
infants on average for 44% of hospital days in the NICUs ward in newborns with extremely low birth
weight, and in up to 11% in newborns with birth weight >2500 g [80,81]. In Poland, the average stay of
a newborn with VLBW with an infection until it reaches 1800 g is 44 days, and the CVC utilization
ratio is 45% [82].
According to recent opinions, it is possible to prevent at least some of the health care-associated
infections in the NICU with active surveillance. A successful program for the neonatal sepsis
surveillance should be based on several activities which include: continuous collection of data on the
incidence of the systemic infections; monitoring the spectrum and sensitivities of organisms grown
from these infections, controlling utilization rates of the invasive devices; and evaluating interventions
and practices implemented to improve the quality of care using bundles. The program should be
discussed and constructed by an infection control team or committee with multilevel representation
from the unit personnel, preferably separately from but in cooperation with the all-hospital committee.
It has been confirmed that the introduction of the bundles is associated with a reduction in
late-onset systemic infections among infants in the NICU [83–85]. The bundles, constructed separately
for individual procedures or periods of care, are written locally to better adapt them to the specificities
of a unit. Bundles are usually procedures based on evidence-based best practices, which improve care
on individual patient. The bundles when applied together, result in substantially greater improvement.
For example, activities of the central line bundle, as described by Pharande, include strict hand hygiene,
maximal sterile barrier precautions, proper skin antisepsis, aseptic technique, optimal site choice
for line insertion, transparent sterile dressing, surveillance, and documentation [85]. According to
the authors, implementation of the bundle during a 15-year period resulted in a constant decline in
the incidence of LOS and CLABSI in their NICU, in spite of an increase in admissions to the NICU,
an increase in central line utilization, and no decrease in the number of high-risk infants. Thus,
implementation of multiple infection control bundle practices, together with well-coordinated team
efforts and the growing engagement of staff, leads to reduction of the nosocomial infection rates and
also strengthening the improvements for a longer time.
The positive results of the implementation of the central line insertion bundle in the NICUs
should lead to future implementation of other preventive practices, based on experiences from adult
ICUs, for example, a postinsertion care bundle which consists of daily inspection of the insertion site;
site care if the dressing is wet, soiled, or has not been changed for seven days; documentation of an
ongoing need for the catheter change; proper application of a chlorohexidine-impregnated sponge at
the insertion site; scrupulous hand hygiene before supervision of the intravenous line; and disinfection
of the infusion hub for 15 s with alcohol scrub before each entry. Such a CVC postinsertion care bundle
was implemented in the adult ICU of the Denver Department of Veterans Affairs and its application
was associated with a significant reduction of CLABSI in a setting in which compliance previously
introduced central line insertion bundle was already high [84].
3.8. Probiotics
Commensal human flora is an extremely valuable first line of defense of the organism, limiting the
possibility of invading foreign microorganisms and activating its own immune system. The newborn
is in the sterile environment of the mother’s womb without exposure to microbes until delivery, and
colonization of the newborn in cases of a healthy pregnancy takes place in direct relationship with the
mother and the home environment. However, newborns admitted to NICUs are subjected to exposure
and colonization with bacterial strains originating from the birth or surgical wards, including from
medical personnel. These microorganisms are often characterized by higher resistance to antibiotics
and multidrug resistance mechanisms, or even higher virulence [86–91].
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Meta-analyses have confirmed a reduction in the risk of NEC through the use of probiotics and
also the risk of LOS [92,93] in preterm infants, although there is disagreement about the latter entity.
Zhang et al. recently stated that probiotic supplementation is safe and may significantly reduce the
incidence of LOS in preterm neonates in the NICU [93] but, conversely, meta-analysis of Olsen et
al. on prophylactic use of probiotics in preterm infants, did not confirmed a significant reduction
in sepsis rates, although a trend toward this effect was noted [94]. Both meta-analyses found a
significant reduction in NEC rates, as well as, in general, mortality among neonates after probiotic
supplementation but probably in exclusively human milk-fed preterm infants only [95].
The postulated mechanisms of the benefits of probiotics include tight junction (gut barrier)
enhancement, modulation of the gut immune system such as toll-like receptor 4 (TLR4), nuclear
factor-B, and proinflammatory cytokines, and direct inhibition of gut pathogens, however, the
commonly accepted theory on mechanisms of LOS, which is mostly caused by CoNS, is that these
skin microbiota members colonize the skin insertion site and catheter hub. From a contaminated hub,
microorganisms migrate along the surface of the catheter and enter the bloodstream. This view is
supported by in vitro studies, demonstrating that CoNS and, particularly Staphylococcus epidermidis,
are able to adhere to plastic surfaces and build a biofilm on them.
The mechanisms of LOS, described above, are evidently not related to the protective activity
of probiotics, which is based on correction of the altered gut microbiota toward the elimination of
pathogens and tighten gut barrier to prevent bacterial translocation from gut to bloodstream. There are,
however, reports supporting the alternative mechanisms of LOS by demonstrating neonatal sepsis
cases which have not been related to catheter use but to translocation of bacteria owing to the increased
intestinal permeability typical in premature neonates [96–98]. Therefore, it is possible that at least
some LOS cases are related to translocation of the potential pathogens colonizing the gut mucosa. Such
a mechanism may explain a positive effect of properly selected probiotics on the gut microbiota and,
consequently, on the prevention of LOS. We recently observed that oral treatment of VLBW neonates
with a mixture of two probiotic bacteria, Bifidobacterium breve and Lactobacillus rhamnosus, was related
to significantly lower rates of LOS caused by staphylococci and especially CoNS. These findings may
support a view that one mechanism of LOS caused by CoNS may be based on translocation of CoNS,
present in large numbers in the gut of VLBW infants, to the bloodstream and not only on colonization
and biofilm building on catheter surfaces by CoNS derived from skin microbiota. This hypothesis
should be verified in specially designed studies.
Since recent studies stress the importance of the intestinal microbiota alterations in premature
neonates as an elementary cause of many diseases in childhood, it seems that a necessary first step is to
design novel approaches that correct the microbiota using selected probiotic bacteria as a pioneering
organism [99]. Such an approach may lead to early probiotic interventions to prevent LOS in high-risk
infants. Well-characterized and clinically proven probiotics should be used for this purpose.
Another concept related to probiotic use is the application of probiotics to pregnant women
for the prevention of general preterm morbidity and mortality. Such a possibility has been tested
and evaluated.
One of the most exciting scientific advances in recent years has been the realization that
commensal microorganisms (our microbiome) play vital roles in human physiology with respect to
nutrition, vitamin synthesis, drug metabolism, protection against infection, and recovery from illness.
Recent data show that loss of “health-promoting” microbes and overgrowth of pathogenic bacteria
(dysbiosis) among patients in the ICU appears to contribute to nosocomial infections, sepsis, and
poor outcomes [100]. Overall, accumulating data regarding probiotic and synbiotic therapy reveal a
need for definitive clinical trials of these therapies, as recently performed in healthy neonates. Future
studies should target administration of probiotics and synbiotics with known mechanistic benefits to
improve patient outcomes. Optimally, future probiotic and synbiotic studies will be conducted using
microbiome signatures to characterize actual ICU dysbiosis and determine, perhaps even personalize,
ideal probiotic and synbiotic therapies.
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Twelve clinical trials have already been analyzed [101] with the authors’ conclusion that although
safe, it is too early to state whether this preventive strategy is beneficial owing to inconsistency and
imprecision of the data. Except for the use of probiotics and prebiotics, prophylactic use of different
drugs which may help to promote a healthy gut microbiota and maturation of the immune system
in preterm infants is recently proposed. Among these, use of lactoferrin as a promising dietary
supplement had been considered, however, the effectiveness of lactoferrin to prevent LOS and NEC in
preterm infants and its safety was regarded as controversial. It is noteworthy to mention, that the latest
meta-analysis confirms that lactoferrin could significantly reduce the incidence of NEC and LOS and
decrease infection-related mortality in premature neonates without obvious adverse effects [102,103].
4. Discussion
Surveillance of infections in many different patient populations is well described and functioning,
starting from uniform, supranational definitions. Unfortunately, for patients in NICU wards, there is
no consensus regarding the principles of surveillance. These differences make it impossible to conduct
an unequivocal assessment of the existing epidemiological and microbiological situation in various
health care systems, as well as the possibility of implementing elements of prevention. Lack of uniform
research tools precludes the design and implementation of supralocal research programs concerning
implementation of the various possible solutions described above (Table 6).
Table 6. Potential interventions in early- and late-onset neonatal sepsis prevention and control.
Implementation of Various BSI Prevention and
Control Strategies References
Decrease of GBS in EOS:
• maternal intrapartum antibiotic prophylaxis
• GBS maternal vaccination (future solution)
[50–55,104]
[59,105–108]
Decrease of E. coli in EOS:
• E. coli maternal vaccination (future solution) [109]
Decrease of EOS:
• risk stratification of asymptomatic neonates for
empirical use of antibiotics [60–62,69,70]
Decrease of LOS:




The most prospective and natural way to prevent sepsis, in neonates at risk in the future, seems to
be the correction of the gut microbiota composition during the very short but critical period of life just
after birth, to enable establishment of bacteria derived from the vaginal microbiota and prevent gut
colonization with bacteria from the hospital environment. There are multiple studies showing that
preterm infants born by cesarean delivery, who are very prone to sepsis, have altered or disrupted gut
microbiota containing potentially pathogenic gram-positive and gram-negative organisms that are
often resistant to multiple antibiotics [67].
Although the molecular mechanisms of the early priming immune system period in humans have
not been defined, thanks to new animal experiments, there are new data showing that mechanisms
of acquiring the gut microbiota in infancy depend on interactions between bacterial, as well as host
factors. It was found that the first microbes introduced into young, germ-free, genetically identical
mice exert the strongest influence on the gut microbiome [102,103].
Recently, a new mechanism has been demonstrated, which regulates bacterial colonization that is
active only during the early neonatal period but also influences life-long microbiota composition. Fulde
et al. showed that expression of the flagellin receptor TLR5 in the gut epithelium of mouse neonates is
age-dependent [110]. They demonstrated, using microbiota transfer experiments in neonate, adult
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wild-type and TLR5-deficientgerm-free mice, that epithelial TLR5-mediated REG3γ production is
critical for the counter-selection of the mucosa-colonizing flagellated bacteria and its expression occurs
in neonatal period. This discovery might explain why environmental factors that disturb establishment
of the normal microbiota in early life period can affect immune homeostasis and health in adulthood.
There is also new evidence suggesting that gut microbiota composition can have a meaningful
impact on the composition of the serum immunoglobulin A (IgA) repertoire and bone marrow plasma
cell pool, which may build protection against systemic infection. Wilmore et al. supplemented the gut
microbiota of conventional mice with selected proteobacteria and demonstrated that the modification
of the microbiota composition caused elevation of the serum IgA concentrations which were correlated
with colonization of the bone marrow by large numbers of IgA-secreting plasma cells and marked
changes in the serum IgA pool [105].
The actual state of knowledge on gut colonization implicates that the gut microbiota composition
is shaped during early infancy but its effect on health is prolonged over adulthood and provides
protection against systemic infections. Thus, proper timing and proper bacteria are the crucial factors
that may determine successful artificial colonization of neonates at risk. This approach will become
more successful when these and other factors are identified in humans and the effects of artificial
colonization are proven in clinical trials.
Although the antibiotic prophylaxis against early onset of GBS infection is effective, antibiotics
are useless in preventing late onset of the disease in neonates. The introduction of a vaccine for
pregnant women in the third trimester is likely to further reduce the burden of disease and provide
benefits beyond the prevention of both EOS and LOS, including prevention of meningitis and disability
following late-onset infections [59,105]. This makes development of the GBS vaccine an important and
effective approach for prophylaxis. Up to now, different multivalent conjugate vaccines containing GBS
polysaccharide antigens representing the main capsular serotypes of the bacteria have been developed.
One of them, a trivalent GBS vaccine, was already successfully evaluated in a phase 1b/2 trial [106].
An immunogenic and protective mucosal vaccine based on inactivated GBS can be as effective as
traditional ones but administered orally [107]. Gupalova recently reported the development of a live
mucosal vaccine based on a probiotic strain, which is able to induce the appearance of pathogen-specific
antibodies owing to the inclusion of antigen of the bacterial pathogen in the structure of the pili
protein gene [108]. For this purpose, BAC protein DNA of GBS was integrated into the gene coding for
the fimbrial protein D2 of Enterococcus faecium L3 [108], however, this approach seems to have some
disadvantages, for example, a risk of using E. faecium, a bacterial species that is an important human
pathogen, is the acquisition of extensive antibiotic resistance [111].
E. coli is the second most common organism associated with EOS and other serious bacterial
infections in neonates. It is postulated that the common use of IAP has changed the incidence of GBS
and E. coli as causes of EOS and LOS. Moreover, increased use of IAP might promote the emergence of
multidrug resistant microorganisms that cause EOS, as well as LOS. The most likely way to prevent
it could be an anti-E. coli vaccine, that should be effective against strains that are associated with
major diseases and resistant to multiple drugs [109,112]. This solution is particularly desirable for
populations of special interest, such as pregnant women at risk of preterm labor.
5. Conclusions
In the present review, we revealed a diverse pattern in the epidemiology and etiology of neonatal
sepsis among 36 OECD countries located on different continents, although the basic data are similar
and remain quite homogenous. This may indicate that it is possible to discuss the potential construction
and implementation of common and effective surveillance programs for infection prevention and
control (IPC) in neonatal wards.
According to the WHO recommendations [1], surveillance of HAI, including neonatal sepsis
(or BSI) is critical to inform and guide IPC strategies. Such surveillance should use standardized
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definitions and methodology not only for continuous, everyday infection surveillance but also as a
method for evaluating the quality of the data.
Further studies and analyses are certainly needed to achieve modern surveillance programs that
will take into account different requirements and various capabilities in the implementation of such
programs. The most important obstacle does not seem to be access to modern medical technologies
but rather the level of knowledge and skills among professional infection control workers, including
interpretation of the microbiological data.
The most prominent differences in the epidemiology of neonatal sepsis collected and presented
in this review were observed not in epidemiological indicators but rather in the microbiology of
infections, especially LOS. Without in-depth studies, it is difficult to find a cause for these discrepancies,
but one possible factor may be differences in the quality of microbiology and laboratory capacities,
which are essential for reliable HAI surveillance. The microbiological data on sepsis etiology and
pathogen resistance patterns, especially according to EOS and LOS, also provide relevant information
on policies of antimicrobial prophylaxis or therapy and antimicrobial resistance-related strategies
and interventions.
New approaches to IPC in NICUs underline the necessity to apply multimodal strategies that take
into account cooperation among different groups of health care personnel. Thus, a uniform training
program in infection control in neonatology is urgently required, together with surveillance programs.
Such programs should also involve modern microbiological approaches based on both classical and
molecular methods of detection, characterization, and epidemiological typing.
Study Limitations
This review is based on full texts (original articles or concise communications) written in English.
We did our best to find useful data published in other languages, as suggested by Higgins et al. [113],
however, not all of the figures we were looking for can be easily found. We were unable to find some
useful information on the methodology of infection control in the non-English sources, and therefore
we decided to limit the reviews to those written in the English language.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/8/10/1750/s1,
Table S1: The study selection process and search strategy.
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